Share on StockTwits

Curis (NASDAQ:CRIS) has been given a consensus rating of “Buy” by the nine ratings firms that are presently covering the company, Analyst RN reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $4.92.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Curis from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 9th. They now have a $2.10 price target on the stock. Analysts at Oppenheimer cut their price target on shares of Curis from $4.50 to $3.00 in a research note on Friday, May 9th. They now have an “outperform” rating on the stock. They noted that the move was a valuation call.

Shares of Curis (NASDAQ:CRIS) opened at 1.83 on Thursday. Curis has a 52-week low of $1.60 and a 52-week high of $4.74. The stock’s 50-day moving average is $1.74 and its 200-day moving average is $2.48. The company’s market cap is $157.3 million. Curis also was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 8,275,495 shares, a growth of 23.7% from the June 13th total of 6,692,521 shares. Approximately 9.9% of the company’s shares are short sold. Based on an average daily trading volume, of 2,469,249 shares, the short-interest ratio is presently 3.4 days.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.06). The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.88 million. During the same quarter in the prior year, the company posted ($0.06) earnings per share. The company’s quarterly revenue was up 42.2% on a year-over-year basis. Analysts expect that Curis will post $-0.21 EPS for the current fiscal year.

Curis, Inc is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.